Ascendis Pharma A/S (ASND) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 6.0% versus a loss of 26.4%. Over five years, SMMT leads with a +233.4% price change compared with +39.2% for ASND. Ascendis Pharma A/S is the larger company by market cap ($15.05 billion vs $13.75 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | SMMT |
|---|---|---|
| Share price | $228.66 | $17.24 |
| Market cap | $15.05B | $13.75B |
| 1-day change | +2.68% | +0.41% |
| YTD return | +4.43% | -1.83% |
| 1-year return | +5.98% | -26.44% |
| 5-year return | +39.19% | +233.40% |
| P/E ratio (TTM) | 17.52 | — |
| Forward P/E | 21.23 | — |
| EPS (TTM) | $13.05 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-1.08B |
| 52-week high | $282.15 | $29.23 |
| 52-week low | $186.05 | $12.07 |
| Distance from 52-week high | -18.96% | -41.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +33.76% | +72.56% |
| Average volume | 662.79K | 5.82M |
| Shares outstanding | 65.80M | 797.75M |
| Employees | 1,189 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASND has outperformed SMMT by 32.4 percentage points over the past year.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
ASND vs SMMT FAQ
Which is bigger, Ascendis Pharma A/S or Summit Therapeutics?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $15.05B compared with $13.75B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, ASND or SMMT?
ASND returned +5.98% over the past 12 months, compared with -26.44% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.